Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORIC |
---|---|---|
09:32 ET | 5832 | 6.98 |
09:34 ET | 434 | 6.98 |
09:38 ET | 500 | 7.125 |
09:39 ET | 540 | 7.16 |
09:41 ET | 1400 | 7.16 |
09:43 ET | 300 | 7.13 |
09:45 ET | 100 | 7.14 |
09:50 ET | 100 | 7.12 |
09:56 ET | 700 | 7.15 |
09:59 ET | 800 | 7.25 |
10:01 ET | 858 | 7.29 |
10:03 ET | 3097 | 7.26 |
10:06 ET | 427 | 7.24 |
10:10 ET | 3476 | 7.25 |
10:12 ET | 300 | 7.225 |
10:14 ET | 3077 | 7.2125 |
10:15 ET | 600 | 7.18 |
10:17 ET | 100 | 7.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oric Pharmaceuticals Inc | 476.7M | -4.0x | --- |
Neurogene Inc | 472.4M | -8.0x | --- |
Corbus Pharmaceuticals Holdings Inc | 483.6M | -6.5x | --- |
Altimmune Inc | 471.5M | -4.6x | --- |
Allogene Therapeutics Inc | 485.5M | -1.3x | --- |
Larimar Therapeutics Inc | 462.6M | -7.7x | --- |
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $476.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.